- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04883463
Neuromodulation to Improve Respiratory Function in Cervical Spinal Cord Injury
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There are five main phases to this study. The first phase is baseline testing, second phase is temporary implant, third phase is post-temporary implant mapping/treatment, fourth phase is permanent implant, and fifth phase is post-permanent implant treatment. During each of the three phases, subjects will have twice weekly laboratory testing sessions and daily home training sessions. As this is a feasibility study, the phases are designed to select for subjects that will be most responsive and will benefit from this strategy.
Phase 1. Baseline testing/training (up to 6 months, UCLA Semel Institute for Neuroscience and Human Behavior), the purpose of which is to ensure that each subject begins with the full benefits achievable by standard rehabilitative respiratory therapy and has stable baseline of function before they begin epidural stimulation. 15 subjects will undergo this phase. Maximum inspiratory and expiratory pressure, resting spontaneous respiratory activity, and respiratory muscle EMG will be measured during this phase. Subjects on ventilator assist mode (unless or until they can sustain adequate respiration on their own) will be monitored via pneumotachometer for respiratory frequency changes. Additionally, subjects will undergo motor and sensory testing. The subjects must show stable respiratory function before implantation, therefore if a subject is showing small improvements at 3 months the subject will continue training until they have reached their maximal effect from training (up to 6 months). Subjects that show stable baseline at 3 months will proceed to Phase 2. If a subject's health worsens, including non-respiratory functioning, subject will be assessed by appropriate physician and testing will be held until subject's health has improved and maintains stable for at least 2 months.
Phase 2. Temporary Implant (1 day, 24 hours overnight stay, UCLA Medical Center, Santa Monica). Subjects will undergo temporary stimulator implant surgery. During surgery, intraoperative mapping with the implant will be performed to demonstrate effective stimulation areas. Up to 12 subjects with evidence of response to baseline testing will undergo this phase from the pool of 12 subjects in Phase 1 above. Response to respiratory training will be based on maximal respiratory effort, respiratory abilities at rest, and respiratory muscle EMG. Subjects will be monitored overnight following surgery as a pre-cautionary measure.
Phase 3. Post-temporary implant mapping/treatment (up to 10 days, UCLA Semel Institute for Neuroscience and Human Behavior) Respiratory ability will be assessed. Respiratory rehabilitation regimen with the stimulator will be used to re-enable respiratory function. Subjects will be tested daily, up to 10 non-consecutive sessions in the clinic. Each session will last up to 2 hours. Subject will have the temporary implant for a minimum of 1 week and maximum of 2 weeks. Maximal respiratory effort and resting respiratory abilities will be evaluated as well as post-implant PROMs will be assessed. Once optimal parameters have been identified, electrode configuration(s) that allow subjects to manipulate their respiratory pattern will be used. Subjects will be allowed to use stimulator at home (daily, with identified parameters) with respiratory training in addition to twice weekly testing. Home use will involve turning on the stimulator, breathing with the ventilator. The same 12 subjects from Phase 2 will undergo this phase.
Phase 4. Permanent implant (1 day, 24 hours overnight stay, UCLA Medical Center, Santa Monica). Subjects will undergo stimulator implant surgery. During surgery, implantation of electrodes will be performed. The ideal placement location will be based on previous temporary trial location. Up to 10 subjects with most connectivity and evidence of response to baseline testing will undergo this phase from the pool of 12 subjects in Phase 3 above. Response to respiratory training will be assessed. Subjects will be monitored overnight following surgery as a pre-cautionary measure.
Phase 5. Post-permanent implant mapping/treatment (up to 12 months, UCLA Semel Institute for Neuroscience and Human Behavior) in which the electrode configuration(s) that activate respiratory muscles will be used. Respiratory rehabilitation regimen with the stimulator will be used to re-enable respiratory function. 10 subjects will be tested up to twice weekly in the clinic for up to 2 hours per session. Respiratory response to stimulation will be assessed. Once optimal parameters have been identified, electrode configuration(s) that allow subjects to manipulate their respiratory pattern will be used. Subjects will be allowed to use stimulator at home (daily, with identified parameters) with respiratory training in addition to twice weekly testing. The same 10 subjects from Phase 4 will undergo this phase.
Timeline. The study is a safety and feasibility trial. This is a single arm implantation of permanent electrode to assess safety and early efficacy of cervical spinal epidural stimulation to improve respiratory function. It is conducted over a period of up to 6 months or 21 months in 1, 2, or 3 periods, respectively (Fig. 3): Phase 1. Baseline training (up to 6 months), Phase 2. Temporary Trial Implant (1 day), Phase 3. Post-temporary trial implant treatment (up to 10 days), Phase 4. Permanent Implant (1 day, with up to 2 months for surgical recovery), Phase 5. Post-permanent implant treatment (up to 12 months). Therefore, 15 subjects will be involved for up to 6 months, while 12 subjects will be involved for up to 7 months, and 10 subjects involved for up to 21 months (18 months of testing with up to 2 months recovery).
Home Use. To ensure safety, the ventilator will provide support for the patient during home use with stimulator turned on, just as it does when epidural stimulation is not on. The patient will not be completely disconnected to the ventilator unless independence from the ventilator is achieved through a gradual and very closely supervised weaning process in which the patient will demonstrate stable O2 saturation and adequate minute ventilation through the stages of weaning. Weaning (and evidence of improved respiratory muscle function) will consist of gradually reducing the level of support delivered by the ventilator while requiring that as weaning occurs, the patient maintains stable minute ventilation on his own.
To ensure safety, these weaning maneuvers will be conducted only with respiratory therapist being present, and an AMBU bag with supplemental O2 will be available. Additionally, for safety, the caregiver will obtain heart rate, blood pressure, temperature at 15 min intervals and O2 saturation continuously, or when there is a change in the ventilator setting. Additionally this will be performed only when the subject is fully conscious, awake, and following commands.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Daniel C Lu, MD, PhD
- Phone Number: 310-267-2975
- Email: DCLu@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90024
- Recruiting
- Semel Institute of Neuroscience at UCLA
-
Contact:
- Daniel Lu, MD
- Phone Number: 310-267-0149
- Email: mailto:DCLu@mednet.ucla.edu
-
Contact:
- Aakash Patel, BS
- Phone Number: 8188526264
- Email: aakashpatel@mednet.ucla.edu
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA Clinical and Translational Research Center
-
Contact:
- Daniel Lu, MD
- Phone Number: 310-267-0149
- Email: DCLu@mednet.ucla.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or Female Age 18-75.
- Diagnosed with cervical spinal cord injury (SCI).
- At least 1 year from initial spinal cord injury.
- Severe respiratory function compromise.
- Able to attend weekly testing sessions for up to 21 months.
- Have intact chest/lung, upper and lower extremity anatomy. The neuromuscular connections between the spinal cord and its effector muscles (respiratory and extremity) are required to be intact.
- Have intact cognitive ability, able to follow commands/voice concerns, and give consent.
Exclusion Criteria:
- History of severe autonomic dysreflexia.
- Phrenic nerve or diaphragm pacer.
- Phrenic nerve paralysis.
- Musculoskeletal dysfunction, unhealed fracture, pressure ulcer, active infection.
- Clinically significant depression or ongoing drug abuse.
- Received lung surgery within one year prior to study enrollment or active intrinsic lung disease (COPD, acute or chronic lung infection, asthma, emphysema, cystic fibrosis, etc).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Epidural Stimulation for Respiratory Function
Self-controlled longitudinal safety and feasibility of stimulation and respiratory training.
|
Epidural electrical stimulation implant weekly sessions for 21 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4
Time Frame: 2.5 years
|
International Standards for Neurological Classification of Spinal Cord Injury/American Spinal Injury Association (ISNCSCI/ASIA)- Neurological motor and sensory function given a score A-E: Timeframe: completed at the beginning and end of the phases.
|
2.5 years
|
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4
Time Frame: 2.5 years
|
Resting Spontaneous Respiratory Activity (measured in Breathes per Minute), Maximal Inspiratory Pressure (measured in cmH2O) and Spinal Cord Independence Measure (a score from 0-100) questionnaire: Timeframe: assessed weekly through the duration of the study.
Data will be analyzed to compare each individual's function to their own at the beginning of the study, during the baseline period.
|
2.5 years
|
Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4
Time Frame: 2.5 years
|
Blood Pressure (mm/Hg): Timeframe: completed at the beginning and end of each testing session.
|
2.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluating Pulmonary Function Throughout the Duration of the Study; 20% increase in minute ventilation.
Time Frame: 2.5 years
|
Tidal Volume = mL Timeframe: assessed weekly through the duration of the study.
|
2.5 years
|
Evaluating Pulmonary Function Throughout the Duration of the Study; 20% increase in minute ventilation.
Time Frame: 2.5 years
|
Maximal Expiratory Pressure = cmH2O Timeframe: assessed weekly through the duration of the study.
|
2.5 years
|
Evaluating Pulmonary Function Throughout the Duration of the Study; 20%
Time Frame: 2.5 years
|
Functional Residual Capacity = mL/kg Timeframe: assessed weekly through the duration of the study.
|
2.5 years
|
Evaluating Pulmonary Function Throughout the Duration of the Study; 20%
Time Frame: 2.5 years
|
Peak Expiratory Flow Rate = mL/min Timeframe: assessed weekly through the duration of the study.
|
2.5 years
|
Evaluating Pulmonary Function Throughout the Duration of the Study; 20%
Time Frame: 2.5 years
|
Minute Volume (measured in L/min): Timeframe: assessed weekly through the duration of the study.
Data for all of the assessments mentioned above will be analyzed to compare each individual's function to their own at the beginning of the study, during the baseline period.Electromyography (EMG): Respiratory muscle activity will be assessed with common practice EMG recording and functional measurements.
Timeframe: assessed weekly through the duration of the study.
|
2.5 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Daniel C Lu, MD, PhD, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-000994
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injuries
-
Khon Kaen UniversityUnknownInjuries, Spinal Cord
-
Universidade do Vale do ParaíbaCompletedInjuries, Spinal Cord
-
InVivo TherapeuticsTerminated
-
Ekso BionicsBurke Medical Research InstituteCompletedInjuries, Spinal CordUnited States
-
ReWalk Robotics, Inc.Unknown
-
Shepherd Center, Atlanta GACompletedInjuries, Spinal Cord
-
Wroclaw Medical UniversityInstitute of Immunology and Experimental Therapy of the Polish Academy of... and other collaboratorsUnknownComplete Spinal Cord InjuriesPoland
-
University of MiamiViewray Inc.Not yet recruitingSpinal Cord Compression | Metastatic Epidural Spinal Cord CompressionUnited States
Clinical Trials on Epidural stimulation
-
Medical University of South CarolinaNational Alliance for Research on Schizophrenia and Depression; MedtronicActive, not recruiting
-
Chinese Academy of SciencesAffiliated Hospital of Logistics University of CAPFUnknown
-
University of LouisvilleNational Heart, Lung, and Blood Institute (NHLBI); National Institute of Neurological... and other collaboratorsRecruiting
-
Susan Harkema PhDNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingSpinal Cord InjuriesUnited States
-
The Methodist Hospital Research InstituteNot yet recruitingSpinal Cord Injuries | Cervical Spinal Cord Injury
-
Stanford UniversityNot yet recruitingAnesthesia, Local | Obstetric PainUnited States
-
Aaron PhillipsRecruitingSpinal Cord InjuriesCanada
-
University of MinnesotaMinneapolis Veterans Affairs Medical Center; Hennepin Healthcare Research Institute and other collaboratorsRecruitingSpinal Cord Injuries | Paraplegia, CompleteUnited States
-
Johns Hopkins UniversityTerminatedGlossopharyngeal Neuralgia | Trigeminal Neuralgia (Burchiel Type I) | Trigeminal Neuralgia (Burchiel Type II) | Trigeminal Neuropathic Pain | Trigeminal Deafferentation Pain | Complex Regional Pain Syndrome (Types I and II, Involving the Upper Extremity) | Upper Extremity Pain Due to Deafferentation... and other conditionsUnited States
-
Buddhist Tzu Chi General HospitalRecruiting